https://clinicaltrials.gov/ct2/results?cond=COVID-19

Primary Completion Date

Outcome Measures

Sponsor/Collaborators

Last Update Posted

Study Documents

https://docs.google.com/spreadsheets/d/15r-EqvDTJJLMhOaEzPjrEcFAMPPPk9-FTgdt-qWG6lY/edit#gid=2022203840&range=2:2

No Results Available

Corona Virus Infection

Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of infusions|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Number of non-invasive ventilation/high flow oxygen free days|Number of oxygenation free days|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first|Ventilator/extracorporeal membrane oxygenation (ECMO) free days

National Institute of Allergy and Infectious Diseases (NIAID)

18 Years to 99 Years   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment

University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Walter Reed Army Institute of Research - Clinical Trials Center, Silver Spring, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|The University of Washington - Virology Research Clinic, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|National Centre for Infectious Diseases (NCID), Singapore, Singapore

Active, not recruiting

The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?

No Results Available

Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom

Incidence of influenza

University College, London

18 Years and older   (Adult, Older Adult)

Observational Model: Case-Control|Time Perspective: Prospective

Accurate Classification System for Patients With COVID-19 Pneumonitis

No Results Available

Renmin Hospital of Wuhan University

Child, Adult, Older Adult

Observational Model: Other|Time Perspective: Retrospective

Renmin Hospital of Wuhan University, Wuhan, Hubei, China

No Results Available

CT Scores Predict Mortality in 2019-nCoV Pneumonia

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Child, Adult, Older Adult

Observational Model: Cohort|Time Perspective: Retrospective

Wuhan third hospital, Wuhan, Hubei, China

Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study

No Results Available

28 day mortality|vasopressor days|days on mechanical ventilation|sequential organ function assessment score|ECMO use|percentage nitric oxide use|percentage free from oxygen supplement

Chinese University of Hong Kong

18 Years and older   (Adult, Older Adult)

Observational Model: Case-Only|Time Perspective: Retrospective

Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong

Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus

No Results Available

Size of lesion area by chest imaging|Blood oxygen saturation|Rate of mortality within 28-days|Sequential organ failure assessment|Side effects in the UC-MSCs treatment group|Electrocardiogram, the changes of ST-T interval mostly|Concentration of C-reactive protein C-reactive protein, immunoglobulin|CD4+ and CD8+ T cells count|Concentration of the blood cytokine (IL-1β, IL-6, IL-8,IL-10,TNF-α)|Concentration of the myocardial enzymes

Puren Hospital Affiliated to Wuhan University of Science and Technology|Wuhan Hamilton Bio-technology Co., Ltd

18 Years to 75 Years   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment

Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China

Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV )

No Results Available

Pneumonia, Pneumocystis|Coronavirus

The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The mortality rate of subjects at weeks 2|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2

Shanghai Public Health Clinical Center

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China

No Results Available

COVID-19|Acute Kidney Injury|Kidney Function

Rate of Acute Kidney Injury|Rate of Death|the length of hospital stay

Zhenhua Zen|Nanfang Hospital of Southern Medical University

18 Years and older   (Adult, Older Adult)

Observational Model: Case-Control|Time Perspective: Retrospective

Hankou Hospital, Wuhan, Hubei, China

No Results Available

Length of hospital stay (days)|Duration (days) of supplemental oxygenation|CT imaging changes|Mortality rate|Time to Clinical Improvement (TTCI)|The pneumonia severity index scores|Time to COVID-19 nucleic acid testing negativity in throat swab|Blood immune cell count|Serum inflammatory markers|Erythrocyte sedimentation rate|Platelet and D-dimer changes|Creatinine changes|Muscle enzymes changes|Usage of antibiotics|Usage of glucocorticoids|Frequency of adverse events

Xiyuan Hospital of China Academy of Chinese Medical Sciences

up to 85 Years   (Child, Adult, Older Adult)

Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Hao Li, Beijing, Beijing, China

No Results Available

Rate of disease remission|Rate of entering the critical stage|Time of entering the critical stage|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of C-reactive protein (CRP) recovery|Rate of Biochemical criterion (CK, ALT, Mb) recovery|Rate of undetectable viral RNA (continuous twice)|Time for hospitalization|Rate of adverse event

18 Years and older   (Adult, Older Adult)

Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Department and Institute of Infectious Disease, Wuhan, Hubei, China

Diagnostic Test: Standard screening strategy|Diagnostic Test: New screening strategy

A New Screening Strategy for 2019 Novel Coronavirus Infection

No Results Available

Novel Coronavirus Infection Pneumonia

Screening accuracy|Cost-effectiveness analysis

Affiliated Hospital to Academy of Military Medical Sciences|The Fifth Medical Center of Chinese PLA General Hospital

Child, Adult, Older Adult

Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening

the Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China

No Results Available

SARS-CoV-2|Outcome, Fatal

all-cause mortality|Severe state

Chongqing Medical University

18 Years and older   (Adult, Older Adult)

Observational Model: Cohort|Time Perspective: Retrospective

The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Enrolling by invitation

No Results Available

COVID-19|Cardiovascular Diseases

The myocardial injury incidence|The risk factors analysis for the death|Clinical characteristics|Clinical course|Cardiovascular comorbidity|Analysis of causes of death

Wuhan Union Hospital, China

18 Years and older   (Adult, Older Adult)

Observational Model: Case-Control|Time Perspective: Retrospective

Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak

No Results Available

Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice

25 Years to 65 Years   (Adult, Older Adult)

Observational Model: Other|Time Perspective: Prospective

Assiut University Hospitals, Assiut, Egypt

No Results Available

Gastrointestinal Disease|Infectious Disease

Technical success|Clinical success|Adverse events

Changhai Hospital

18 Years to 80 Years   (Adult, Older Adult)

Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other

Changhai Hospital, Shanghai, China

Other: Questionnaire with precaution information|Other: Experimental: Questionnaire without precaution information

No Results Available

Differences of attitude about blood donation towards different questionnaires|Rates of blood donation during 3 weeks

Guangzhou Blood Center

18 Years to 60 Years   (Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research

Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of Novel Coronavirus Infection

No Results Available

2019-nCoV Pneumonia

Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event

The Ninth Hospital of Nanchang|Ascletis Pharmaceuticals Co., Ltd.

18 Years to 75 Years   (Adult, Older Adult)

Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China

Diagnostic Test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals

Impact of Swab Site and Sample Collector on Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals

No Results Available

Infections, Respiratory|Fever|Cough

Accuracy of patient administered tests

Dr. Deneen Vojta|Quest Diagnostics|Bill and Melinda Gates Foundation|UnitedHealth Group

Child, Adult, Older Adult

Observational Model: Case-Only|Time Perspective: Retrospective

Everett Clinic, Seattle, Washington, United States

Active, not recruiting

No Results Available

COVID-19|Hypertension

Rate of Death|the severity of pneumonia

Zhenhua Zen|Nanfang Hospital of Southern Medical University

18 Years to 100 Years   (Adult, Older Adult)

Observational Model: Case-Control|Time Perspective: Retrospective

Hankou Hospital, Hankou, Hubei, China

Prognositc Factors in COVID-19 Patients Complicated With Hypertension

No Results Available

Occupancy rate in the intensive care unit (ICU)|Mechanical Ventilation|Death|All cause mortality|Time from onset of symptoms to main outcome and its components|Time to Clinical Recovery

Chongqing Medical University

18 Years to 100 Years   (Adult, Older Adult)

Observational Model: Cohort|Time Perspective: Retrospective

The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

No Results Available

Coronavirus Disease 2019

Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation

Guangzhou Institute of Respiratory Disease|Huizhou Municipal Central Hospital

Child, Adult, Older Adult

Observational Model: Cohort|Time Perspective: Retrospective

HuiZhou Municipal Central Hospital, Huizhou, Guangdong, China

Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)

Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19

No Results Available

Time course of body temperature (fever)|Viral load over time|P/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Angiotensin-converting enzyme 2 (ACE2) changes over time|Interleukin 6 (IL-6) changes over time|Interleukin 8 (IL-8) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-α (TNF-α) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Angiopoietin-2 changes over time|Frequency of adverse events and severe adverse events

The First Affiliated Hospital of Guangzhou Medical University

18 Years to 80 Years   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Phase 2|Phase 3

Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia

No Results Available

Coronavirus Infections

Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio|Degree of dyspnea (Liker scale)|Degree of dyspnea (VAS)|The area of lung lesions on Chest CT|The degree of lung exudation on Chest CT|SpO2|PaO2|CRP|hs-CRP|All-cause mortality

Qilu Hospital of Shandong University

18 Years to 80 Years   (Adult, Older Adult)

Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Qilu Hospital of Shandong University, Jinan, Shandong, China

No Results Available

SARS Pneumonia

arrest in deterioration of pulmonary function|improving in pulmonary function|need of oro-tracheal intubation|death

Università Politecnica delle Marche|Azienda Ospedaliera Ospedali Riuniti Marche Nord

18 Years to 90 Years   (Adult, Older Adult)

Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Università Politecnica delle Marche, Ancona, AN, Italy

"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04315480/Prot_000.pdf

Clinical Characteristics and Prognostic Factors of Patients With COVID-19

No Results Available

Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation

Shanghai 10th People's Hospital|Chibi People's Hospital, Hubei Province

18 Years and older   (Adult, Older Adult)

Observational Model: Cohort|Time Perspective: Retrospective

Shanghai 10th People's Hospital, Shanghai, Shanghai, China

No Results Available

2019-nCov|Remdesivir

Time to Clinical Improvement (TTCI) [Censored at Day 28]|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours.|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events

Capital Medical University

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Bin Cao, Beijing, Beijing, China

A Longitudinal Study of SARS-CoV-2 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research

No Results Available

SARS-CoV Infection

Detection of SARS-CoV-2 virus|Trajectory of COVID-19 and antibody development

Dr. Deneen Vojta|PATH|Mayo Clinic|Bill and Melinda Gates Foundation|UnitedHealth Group

Child, Adult, Older Adult

Observational Model: Case-Only|Time Perspective: Prospective

Everett Clinic, Seattle, Washington, United States

ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19

No Results Available

Severe COVID-19|Death

Neuromed IRCCS

Child, Adult, Older Adult

Observational Model: Case-Control|Time Perspective: Retrospective

IRCCS Neuromed, Department of Epidemiology and Prevention, Pozzilli, Italy

No Results Available

Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen|Change (reduction) in 2019-nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Frequency of requirement for mechanical ventilation|Frequency of serious adverse events

Capital Medical University|Chinese Academy of Medical Sciences

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Jin Yin-tan hospital, Wu Han, Hubei, China

No Results Available

Coronavirus|Diabetes

Assess the prevalence of severe forms among hospitalized patients with diabètes and COVID-19|describe the clinical and biological characteristics of hospitalized subjects with diabetes and COVID-19|describe the prognosis of hospitalized subjects with diabetes and COVID-19|describe the care management of hospitalized subjects with diabetes and COVID-19

Nantes University Hospital

Child, Adult, Older Adult

Observational Model: Cohort|Time Perspective: Other

Enrolling by invitation

Drug: Bromhexine Hydrochloride Tablets|Drug: Arbidol Hydrochloride Granules|Drug: Recombinant Human Interferon α2b Spray

Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)

No Results Available

Novel Coronavirus Pneumonia|2019-nCoV

Time to clinical recovery after treatment|Rate of aggravation|Clinical remission rate|Dynamic changes of oxygenation index|Time to cure|rate to cure|Time to defervescence|Time to cough remission|Time to dyspnea remission|Days of supplemental oxygenation|Rate of patients with requring supplemental oxygen|Rate of patients with mechanical ventilation|Time of negative COVID-19 nucleic acid results|Rate of negative COVID-19 nucleic acid results|Rate of ICU admission|28-day mortality

Second Affiliated Hospital of Wenzhou Medical University|WanBangDe Pharmaceutical Group Co.,Ltd.

18 Years to 80 Years   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

The Second AffIliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia

No Results Available

Virus; Pneumonia

GHQ-12(general health questionnaire-12)|IES-R(Impact of Event Scale-Revised)

Huazhong University of Science and Technology

Child, Adult, Older Adult

Observational Model: Case-Only|Time Perspective: Prospective

Tongji Hospital，Tongji Medical College Affiliated，Huazhong University of Science ＆ Technology, Wuhan, Hubei, China

Acute Respiratory Failure and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Real Life

No Results Available

Coronavirus Infections|Respiratory Failure|Ventilator Lung

Real life data of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection|in-hospital mortality|30 days mortality|6 months mortality|Intubation rate|Time to Intubation|Time to ventilation|Non invasive to Invasive time|Recovery rate|Recurrence rate|Risk factor for COVID19|Blood tests and outcome|Antiviral therapy|Coinfections|Radiological findings|Ultrasound findings|Myocardial injury|Medical management

University of Milan

18 Years and older   (Adult, Older Adult)

Observational Model: Cohort|Time Perspective: Prospective

Luigi Sacco University Hospital, Milan, Lombardia, Italy

Other: pregnant women with laboratory-confirmed 2019-n-CoV

Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.

No Results Available

Maternal and perinatal outcomes

Federico II University

18 Years to 50 Years   (Adult)

Observational Model: Cohort|Time Perspective: Other

University of Naples Federico II, Napoli, Italy

Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2

No Results Available

Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection|Coronavirus|Coronavirus Infections

Incidence of COVID19 Disease among those who are asymptomatic at trial entry|Ordinal Scale of COVID19 Disease Severity at 14 days among those who are symptomatic at trial entry|Incidence of Hospitalization|Incidence of Death|Incidence of Confirmed SARS-CoV-2 Detection|Incidence of Symptoms Compatible with COVID19 (possible disease)|Incidence of All-Cause Study Medicine Discontinuation or Withdrawal|Overall symptom severity at 5 and 14 day

University of Minnesota

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Internet, New York, New York, United States

No Results Available

Improved clinical status|Return to room air|SARS-CoV-2 RNA|Discharge|Death

Renmin Hospital of Wuhan University|Ansun Biopharma, Inc.

18 Years to 70 Years   (Adult, Older Adult)

Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Renmin Hospital of Wuhan University, Wuhan, Hubei, China

Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus

No Results Available

Rate of recovery from positive to negative swaps|Fever to normal temperature in days|Resolution of lung inflammation in CT or X ray|30 days mortality rate|Number of days till reaching negative swab results

Misr University for Science and Technology

5 Years to 75 Years   (Child, Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment

Mahmoud Tantawy, Cairo, Egypt

Phase 2|Phase 3

Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure

No Results Available

Coronavirus Infections|Respiratory Infection Virus

Lower Murray lung injury score|The difference of PaO2/FiO2 between two groups|Lower Sequential Organ Failure Assessment (SOFA) score|Mechanical ventilation support|Clearance of noval coronavirus|All-cause mortality

Peking Union Medical College Hospital|Zhongda Hospital|Zhongnan Hospital|Renmin Hospital of Wuhan University

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Medical ICU,Peking Union Medical College Hospital, Beijing, Beijing, China

Active, not recruiting

Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study

No Results Available

COVID-19|Physician-Patient Relations

Evaluation of covid-19 knowledge level of turkish physicians

Kanuni Sultan Suleyman Training and Research Hospital

25 Years to 55 Years   (Adult)

Observational Model: Ecologic or Community|Time Perspective: Prospective

Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey

No Results Available

Accuracy of nCapp COVID-19 risk diagnostic model

Chinese Alliance Against Lung Cancer|Shanghai Respiratory Research Institution

18 Years to 90 Years   (Adult, Older Adult)

Observational Model: Cohort|Time Perspective: Prospective

Renmin Hospital of Wuhan University, Wuhan, Hubei, China

The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19

No Results Available

COVID-19 Thalidomide

Time to Clinical Improvement (TTCI)|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events|Serum TNF-α, IL-1β, IL-2, IL-6, IL-7, IL-10, GSCF, IP10#MCP1, MIP1α and other cytokine expression levels before and after treatment

First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Washed Microbiota Transplantation for Patients With 2019-nCoV Infection

No Results Available

COVID-19 Complicated With Refractory Intestinal Infections

Number of participants with improvement from severe type to common type

The Second Hospital of Nanjing Medical University

14 Years to 70 Years   (Child, Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Drug: PD-1 blocking antibody+standard treatment|Drug: Thymosin+standard treatment|Other: standard treatment

No Results Available

2019 nCoV, PD-1

lung injury score|absolute lymphocyte counts|serum level of CRP, PCT and IL-6|SOFA score|all cause mortality rate|ventilation free days|ICU free days

Southeast University, China

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment

Phase 2|Phase 3

The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia

No Results Available

Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of Adverse Drug Events|Frequency of Serious Adverse Drug Events

Peking Union Medical College Hospital|Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

No Results Available

SARS-CoV-2 Pneumonia

Respiratory failure|Occurence of bacterial superinfection

University of Bologna

18 Years to 99 Years   (Adult, Older Adult)

Observational Model: Cohort|Time Perspective: Retrospective

University of Bologna - Department of Medical and Surgical Sciences, Bologna, Italy

Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.

No Results Available

Pharmacological Action

The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.|The percentage of patients achieving the remission; CRP, IL-6 and TNFα values at baseline and during the treatment course; the number of AEs.

18 Years to 85 Years   (Adult, Older Adult)

Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Fabrizio Cantini, Prato, Tuscany, Italy

Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients

No Results Available

2019-nCoV|Immunoglobulin of Cured Patients

Time to Clinical Improvement (TTCI)|Clinical status assessed by the ordinal scale|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|The lesions of the pulmonary segment numbers involved in pulmonary CT [ every 7 days]|Time to 2019-nCoV RT-PCR negativity in respiratory tract specimens [every 3 days]|Dynamic changes of 2019-nCoV antibody titer in blood|Length of hospital stay (days)|All cause mortality

Wuhan Union Hospital, China

18 Years and older   (Adult, Older Adult)

Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Other: pregnant women with laboratory-confirmed 2019-n-CoV

Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy

No Results Available

Maternal and perinatal outcomes

Federico II University

Child, Adult, Older Adult

Observational Model: Cohort|Time Perspective: Other

Gabriele Saccone, Napoli, Italy

Active, not recruiting

Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus

No Results Available

Pneumonia Caused by Human Coronavirus

Mortality|The time interval of Nucleic acid detection become negative

Fujian Provincial Hospital

18 Years to 75 Years   (Adult, Older Adult)

Observational Model: Other|Time Perspective: Retrospective

Fujian Provincial Hospital, Fuzhou, Fujian, China

Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia

No Results Available

Pneumonia, Viral|Pneumonia, Ventilator-Associated

Oxygenation index|28 day mortality|Hospital stay|2019-nCoV nucleic acid test|Improvement of lung imaging examinations|White blood cell count|Lymphocyte count|Lymphocyte percentage|Procalcitonin|interleukin(IL)-2|IL-4|IL-6|IL-8|IL-10|tumor necrosis factor(TNF)-α|γ-interferon(IFN)

ZhiYong Peng|Tuohua Biological Technology Co. Ltd|Zhongnan Hospital

18 Years to 75 Years   (Adult, Older Adult)

Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention

Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China

No Results Available

Serogroup C Meningococcal Meningitis|Diphtheria|COVID-19

Feasibility of developing a UK based sero-epidemiological programme in 0-24 year olds|Feasibility of developing a UK based sero epidemiological survey in 0-24 year olds|Recruitment rate|Cost|To assess, in relevant age groups, immunity against infections and vaccine preventable diseases|Sera collection

University of Oxford

up to 24 Years   (Child, Adult)

Observational Model: Other|Time Perspective: Prospective

Centre for Clinical Vaccinology & Tropical Medicine (CCVTM), Oxford, Oxfordshire, United Kingdom

No Results Available

Cardiovascular Death; Major Adverse Cardiovascular Events

Cardiovascular Death|Major Adverse Cardiovascular Events|Times From symptom onset to hospital arrival|Anxiety

Qilu Hospital of Shandong University

Child, Adult, Older Adult

Observational Model: Case-Only|Time Perspective: Prospective

Affiliated Hospital of Binzhou Medical Universty, Binzhou, Shandong, China|Heze Municipal Hospital, Heze, Shandong, China|Shandong University Qilu Hospital, Jinan, Shandong, China|Jinan Central Hospital, Shandong University, Jinan, Shandong, China|First Hospital Affiliated with Shandong First Medical University, Jinan, Shandong, China|Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China|The Second Hospital of Shandong University, Jinan, Shandong, China|Jining Hospital of Traditional Chinese Medicine, Jining, Shandong, China|Qihe People's Hospital, Qihe, Shandong, China|Affiliated Hospital of Qingdao University Medical College, Qingdao, Shandong, China|Weihai Municipal Hospital, Weihai, Shandong, China|Central Hospital of Zibo, Zibo, Shandong, China

Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.

No Results Available

The relief / disappearance rate of main symptoms|Chest CT absorption|Virus antigen negative conversion rate|Clinical effective time: the average effective time|The number of severe and critical conversion cases|Incidence of complications|Traditional Chinese Medicine Syndrome Score

Jiangsu Famous Medical Technology Co., Ltd.

18 Years to 75 Years   (Adult, Older Adult)

Observational Model: Cohort|Time Perspective: Prospective

Huai'an fourth people's Hospital, Huaian, Jiangsu, China

Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)

No Results Available

Viral load|Viral load change|Time to clinical improvement (TTCI)|Percentage of progression to supplemental oxygen requirement by day 7|Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7|Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission|Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7|adverse effects|Concentration of Lopinavir/ritonavir and hydroxychloroquine

Asan Medical Center

16 Years to 99 Years   (Child, Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)

No Results Available

Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14|Proportion of Participants With Treatment Emergent Adverse Events Leading to Study Drug Discontinuation

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Stanford Hospital, Stanford, California, United States|University of Chicago, Chicago, Illinois, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|New York Presbyterian Hospital/Weill Cornell Medical College, New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|The Miriam Hospital, Providence, Rhode Island, United States|Baylor University Medical Center, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|ASST degli Spedali Civili di Brescia - Spedali Civ, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

No Results Available

Proportion of Participants Discharged by Day 14|Proportion of Participants With Treatment Emergent Adverse Events Leading to Study Drug Discontinuation

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Stanford Hospital, Stanford, California, United States|University of Chicago, Chicago, Illinois, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|The Miriam Hospital, Providence, Rhode Island, United States|Baylor University Medical Center, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Providence Medical Research Center, Everett, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Azienda Ospedaliero Universitaria di Parma, Parma, Iran, Islamic Republic of|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|ASST Fatebenefratelli Sacco, Milano, Italy|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario La Paz, Madrid, Spain|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan

NestCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia

No Results Available

COVID-19 Pneumonia

Disappear time of ground-glass shadow in the lungs|Rate of mortality within 28-days|Change of Clinical symptoms including duration of fever and respiratory|Time of nucleic acid turning negative|CD4+ and CD8+ T cell count|Changes of blood oxygen|Side effects in the treatment group

Azidus Brasil|Cellavita Pesquisa Científica Ltda|Hospital Vera Cruz

18 Years and older   (Adult, Older Adult)

Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil

No Results Available

COVID-19|Novel Coronavirus Pneumonia

the incidence of treatment failure in 14 days|clinical cure incidence in 14 days|the duration of virus change to negative|mortality at day 30|ICU admission rate in 30 days

Beijing Chao Yang Hospital

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Hubei province hospital of integrated Chinese & Western Medicine, Wuhan, Hubei, China|Yichang first people's Hospital, Yichang, Hubei, China|Renmin Hospital of Wuhan University, Wuhan, China|Tianyou Hospital Affiliated to Wuhan University of science and technology, Wuhan, China|Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Wuhan, China

Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab

Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019

No Results Available

Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time

Peking University First Hospital

18 Years to 65 Years   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Anhui Medical University Affiliated First Hospital, Hefei, Anhui, China|Guiqiang Wang, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Cancer Hospital Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei, China|West Hospital Union Hospital Huazhong University of Science and Technology, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China

Drug: ASC09F+Oseltamivir|Drug: Ritonavir+Oseltamivir|Drug: Oseltamivir

A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia

No Results Available

2019-nCoV Pneumonia

Rate of comprehensive adverse outcome|Time of clinical remission|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no need for oxygen inhalation|Rate of undetectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Rate and time of CRP,ES,Biochemical criterion(CK,ALT,Mb)recovery

18 Years to 55 Years   (Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment

Department and Institute of Infectious Disease, Wuhan, Hubei, China

No Results Available

Coronavirus Infection

Pulse oximetry level|Respiratory rate|Heart rate|Blood pressure|Systemic carbon dioxide

TMC HealthCare|PEEP Medical, LLC

18 Years and older   (Adult, Older Adult)

Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

TMC HealthCare, Tucson, Arizona, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

Drug: recombinant human interferon Alpha-1b|Drug: thymosin alpha 1

Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff

No Results Available

2019 Novel Coronavirus Infection

new-onset COVID-19|Number of Participants with coronavirus related symptoms|Number of Participants with adverse effect

Shanghai Jiao Tong University School of Medicine

18 Years to 65 Years   (Adult, Older Adult)

Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention

Taihe Hospital, Shiyan, Hubei, China

Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool

No Results Available

Critically Ill|Coronavirus Infections

28-day all cause mortality|All cause infection|The rate of complications|Length of ICU stay|Duration of mechanical ventilation

Peking University Third Hospital|School of Pharmaceutical Sciences, Peking University, Beijing, China|Department of Medicine, Queen's University, Kingston, Ontario, Canada

18 Years and older   (Adult, Older Adult)

Observational Model: Cohort|Time Perspective: Prospective

Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection (CoV-CONTACT-SERO)

No Results Available

Number of Participants with positive serology in the 90 days following last contact|fever > 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhea

Institut National de la Santé Et de la Recherche Médicale, France

Child, Adult, Older Adult

Observational Model: Cohort|Time Perspective: Prospective

CIC 1425, Paris, France

Drug: Xiyanping injection|Drug: Lopinavir / ritonavir, alpha-interferon nebulization

Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia

No Results Available

2019 Novel Coronavirus Pneumonia

Clinical recovery time|Complete fever time|Cough relief time|Virus negative time|Incidence of severe or critical neocoronavirus pneumonia

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

18 Years to 70 Years   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19

No Results Available

FLUS findings and respiratory failure|FLUS findings and chest x-ray.|FLUS findings and admission to intensive care.|FLUS findings and SAR-CoV-2 PCR-test result.

University of Aarhus

18 Years and older   (Adult, Older Adult)

Observational Model: Cohort|Time Perspective: Prospective

Lungemedicinsk Forskningsafdeling. Aarhus University Hospital, Aarhus, Denmark|Regionshospitalet Horsens., Horsens, Denmark

Other: Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.

Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress

No Results Available

International Physical Activity Questionnaire (IPAQ)|Health-Related Quality of Life SF-12 Scale|Beck Depression Scale

Istanbul University-Cerrahpasa

18 Years to 55 Years   (Adult)

Observational Model: Case-Only|Time Perspective: Cross-Sectional

Istanbul University Cerrahpasa, Istanbul, Turkey

An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection

No Results Available

Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection

Cohort A: reduction of the need of invasive ventilation or 30-day mortality|Cohort B: reduction of mortality|Cohort A Reduction of the need of time of ventilatory support|Cohort B Percentage of patients that undergo to tracheostomy|Cohort B Improvement of the lung function assessed by radiologic findings

A.O. Ospedale Papa Giovanni XXIII

18 Years and older   (Adult, Older Adult)

Observational Model: Case-Control|Time Perspective: Retrospective

ASST - Papa Giovanni XXIII, Bergamo, Italy

Diagnostic Test: Electrocardiogram and transthoracic echocardiography

Joint Use of Electrocardiogram and Transthoracic Echocardiography in an Observational Study to Monitor Cardio-vascular Events in Patients Diagnosed With COVID-19

No Results Available

COVID-19|Myocardial Injury|Myocarditis

Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay|Description of cardiovascular outcomes in the cohort|Prognosis role of baseline cardio-vascular caracteristics on patients survival|Prediction of cardio-vascular events with baseline characteristics|Characterization of inflammation on cardio-vascular outcomes

Groupe Hospitalier Pitie-Salpetriere

16 Years and older   (Child, Adult, Older Adult)

Observational Model: Cohort|Time Perspective: Prospective

Clinical Investigation Center Pitié-Salpêtrière, Paris, France

Enrolling by invitation

Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial

No Results Available

Coronavirus Infections

Mortality changes in day 10|Mortality changes in day 30|Changes of C-reactive protein|Changes of Interleukin 6|Changes of tumor necrosis factor-α|Changes of PaO2/FiO2 Ratio|Changes of CD3|Changes of CD4|Changes of CD8|Changes of CD4/CD8 ratio|Changes of lymphocyte count|Changes of leukocyte count|Changes of alanine transaminase (ALT)|Changes of aspartate transaminase (AST)|Changes of alkaline phosphatase (ALP)|Changes of lactate dehydrogenase (LDH)|Changes of creatine phosphokinase (CPK)|Changes of Creatine kinase-MB (CK-MB)|Changes of Specific IgG|Radiological findings|Number of days ventilated|Length of hospitalization

Mazandaran University of Medical Sciences

30 Years to 70 Years   (Adult, Older Adult)

Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran, Islamic Republic of

Phase 2|Phase 3

Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome

No Results Available

Severe Acute Respiratory Syndrome (SARS) Pneumonia|Coronavirus Infections|ARDS, Human

Composite primary end-point|death|Admission to ICU|Endotracheal intubation (invasive mechanical ventilation)|reduction of C-reactive protein or CRP|Reduction of mechanical ventilation

University of Trieste

18 Years to 80 Years   (Adult, Older Adult)

Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Marco Confalonieri, Trieste, TS, Italy

"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/ICF_001.pdf

No Results Available

National Early Warning Score equal to zero|C-reactive proteins|Lymphocyte Count|d-dimers

Prof. Dr. Umar Farooq|Ayub Medical College, Abbottabad

18 Years to 50 Years   (Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment

Ayub Teaching Institution, Abbottābād, K.p.k, Pakistan

The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia

No Results Available

COVID-19 Thalidomide

Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence

First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia

No Results Available

COVID-19|Endotracheal Intubation

Success rate of intubation|Infection rate of Anesthesiologist|Extubation time

18 Years to 90 Years   (Adult, Older Adult)

Observational Model: Case-Only|Time Perspective: Prospective

No Results Available

All-cause mortality|Composite outcome:composite of intubation for mechanical ventilation or death.

Estudios Clínicos Latino América|Population Health Research Institute

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Drug: Tocilizumab|Other: Standard of care|Procedure: Continuous renal replacement therapy

Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19

No Results Available

Covid-19|SARS|Cytokine Storm|Cytokine Release Syndrome|Tocilizumab

Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14|Duration of hospitalization|Proportion of Participants With Normalization of Fever Through Day 14|Change from baseline in white blood cell and differential count|Time to first negative in 2019 novel Corona virus RT-PCR test|All-cause mortality|Change from baseline in hsCRP|Change from baseline in cytokines IL-1β, IL-10, sIL-2R, IL-6, IL-8 and TNF-α|Change from baseline in proportion of CD4+CD3/CD8+CD3 T cells

Tongji Hospital|Hubei Xinhua Hospital|Wuhan No.1 Hospital|Wuhan central hospital

18 Years to 80 Years   (Adult, Older Adult)

Observational Model: Cohort|Time Perspective: Retrospective

Tongji Hospital, Wuhan, Hubei, China

No Results Available

Coronavirus Infections|Pneumonia, Viral

Clinical improvement|Hospital discharge|Death|Clinical status|Mechanical venhtilation|Hospitalization|Time from death|Negativization COVID 19|Fever

Lucio Manenti|Azienda Ospedaliero-Universitaria di Parma

18 Years to 85 Years   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients

No Results Available

COVID-19|Recombinant Human Interferon α1β

The incidence of side effects|Time from patient enrollment to clinical remission|Proportion of patients with normal body|Proportion of patients without dyspnea|Proportion of patients without cough|Proportion|The negative conversion rate of new coronavirus nucleic acid|Frequency of serious adverse drug events.

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Active, not recruiting

No Results Available

death|time to extubation|length of intensive care unit stay|time to CPAP weaning|viral load|immune response

Foundation IRCCS San Matteo Hospital|OSPEDALE CARLO POMA ASST MANTOVA|OSPEDALE MAGGIORE LODI|OSPEDALE ASST CREMONA

18 Years and older   (Adult, Older Adult)

Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Catherine Klersy, Pavia, PV, Italy

Phase 1|Phase 2

Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells

A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19

No Results Available

Clinical response|Side effects in the treatment group

Chongqing Public Health Medical Center|Chongqing Sidemu Biotechnology Technology Co.,Ltd.

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Chongqing Public Health Medical Center, Chongqing, China

Device: high flow nasal cannula (HFNC)|Procedure: Prone positioning (PP)

Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS

No Results Available

Prone Positioning|High Flow Nasal Cannula|Acute Respiratory Distress Syndrome|Corona Virus Infection

Treatment failure|Intubation rate|Efficacy of PP

Rush University Medical Center|Medical College of Wisconsin

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Rush University Medical Center, Chicago, Illinois, United States|Medical College of Wisconsin, Wauwatosa, Wisconsin, United States

No Results Available

Coronavirus|Depression|Anxiety|Stress

Assessment of COVID-19 situation|Depression, Anxiety and Stress Scale|Familiarity and trust in COVID-related rumours|Availability heuristic

Jean Liu|Yale-NUS College

21 Years and older   (Adult, Older Adult)

Observational Model: Cohort|Time Perspective: Cross-Sectional

Yale-NUS College, Singapore, Singapore

Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection

No Results Available

The incidence of composite adverse outcome|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requring supplemental oxygen|Rate of undectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Time and rate of laboratory indicators related to disease improvement to return to normal

First Affiliated Hospital of Zhejiang University|Ascletis Pharmaceuticals Co., Ltd.

18 Years to 75 Years   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia

No Results Available

Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality

Ruijin Hospital|Shanghai Public Health Clinical Center|Wuhan Jinyintan Hospital, Wuhan, China|Cellular Biomedicine Group Ltd.

18 Years to 75 Years   (Adult, Older Adult)

Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children

No Results Available

Proportion of asymptomatic children or children with mild respiratory symptoms|Confirmed Cov2-SARS cases by age|Confirmed Cov2-SARS cases by symptoms|Viral load|Other respiratory viruses

Centre Hospitalier Intercommunal Creteil|ACTIV

6 Months to 15 Years   (Child)

Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic

Cabinet du Dr Belaroussi, Boulogne, France|Cabinet du Dr Derkx, Champigny-sur-Marne, France|Cabinet du Dr Coicadan, Chennevières-sur-Marne, France|Cabinet du Dr Corrard, Combs-la-Ville, France|53 Boulevard De La Liberté, Les Lilas, France|157 Avenue du Général Leclerc, Maisons-Alfort, France|Cabinet du Dr Bodin, Montgeron, France|Cabinet du Dr Deberdt, Nogent-sur-Marne, France|Cabinet du Dr Wollner, Nogent-sur-Marne, France|Cabinet du Dr D'acremont, Paris, France|Cabinet du Dr Romain, Paris, France|Cabinet du Dr Turberg-Romain, Paris, France|Cabinet du Dr Michot, Paris, France|Cabinet du Dr Cohen, Saint-Maur-des-Fossés, France|Cabinet de Pédiatrie des Docteurs Ravilly et Bessa, Villejuif, France|13 Villa Beauséjour, Vincennes, France

Diagnostic Test: New QIAstat-Dx fully automatic multiple PCR detection platform

Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System

No Results Available

Sensitivity， spectivity turnaround time of the New QIAstat-Dx fully automatic multiple PCR detection platform

Huashan Hospital

16 Years to 100 Years   (Child, Adult, Older Adult)

Observational Model: Cohort|Time Perspective: Retrospective

Huashan Hospital of Fudan University, Shanghai, Shanghai, China

Drug: Abidol hydrochloride|Drug: Oseltamivir|Drug: Lopinavir/ritonavir

A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia

No Results Available

Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery|Rate of undetectable viral RNA

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment

Department and Institute of Infectious Disease, Wuhan, Hubei, China

Drug: Abidol hydrochloride|Drug: Abidol Hydrochloride combined with Interferon atomization

A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia

No Results Available

Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion (CK,ALT,Mb)recovery|Rate of undetectable viral RNA

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment

Department and Institute of Infectious Disease, Wuhan, Hubei, China

The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia

No Results Available

2019-nCoV Severe Pneumonia

Rate of disease remission|Rate and time of entering the critical stage|Rate of normal tempreture|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of laboratory indicator recovery|Rate of undetectable viral RNA

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment

Department and Institute of Infectious Disease, Wuhan, Hubei, China

No Results Available

Pneumonia, Viral|Hypertension|Diabetes Mellitus|Obesity|Cardiovascular Diseases|Obstructive Lung Disease

mean recovery rate|comparison of time to improvement|organ failure|efficacy of treatments

Catholic University of the Sacred Heart

18 Years to 100 Years   (Adult, Older Adult)

Observational Model: Case-Control|Time Perspective: Prospective

Drug: Antiviral treatment and prophylaxis|Other: Standard Public Health measures

Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention

No Results Available

Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3|The mortality rate of subjects at weeks 2|Proportion of participants that drop out of study|Proportion of participants that show non-compliance with study drug

Fundacio Lluita Contra la SIDA|Germans Trias i Pujol Hospital|Department of Health, Generalitat de Catalunya|FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA|Laboratorios Gebro Pharma SA|Laboratorios Rubió|Institut Catala de Salut

18 Years and older   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention

CAP II Sant Fèlix, Sabadell, Barcelona, Spain|Gerència Territorial Catalunya Central, Sant Fruitós De Bages, Barcelona, Spain|Centre de Salut Isabel Roig-Casernes de Sant Andreu, Barcelona, Spain

The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19

No Results Available

Coronavirus Disease 2019|Novel Coronavirus Pneumonia

The time to oxygen saturation recovery to normal level (≥97%)|The proportion of patients with normal level of oxygen saturation(≥97%)|The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, etc.|The time to the myocardial enzyme spectrum recovery to normal after treatment|The proportion of the patients with normal myocardial enzyme spectrum after treatment|The time to the electrocardiogram recovery to normal level after treatment|The proportion of the patients with normal electrocardiogram after treatment|The time to the hemodynamics recovery to normal after treatment|The proportion of the patients with normal hemodynamics after treatment|The time to exacerbation or remission of the disease after treatment;|The proportion of the patients with exacerbation or remission of disease after treatment|The proportion of patients who need other treatment (e.g. heparin, anticoagulants) due to microcirculation disorders|The all-cause mortality rate|The proportion of patients with acidosis|The total duration of the patients in-hospital|The total duration of oxygen inhalation during treatment|The oxygen flow rate during treatment|The oxygen concentration during treatment

Tasly Pharmaceuticals, Inc.

18 Years to 85 Years   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT

No Results Available

COVID-19 Pneumonia

The time from randomization to clinical improvement

Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Ialy Moriggia Pelascini Gravedona Hospital S.p.A|Wuhan University|Jiangbei Union Hospital of Huazhong University of science and technology|Shandong Provincial Chest Hospital

18 Years to 80 Years   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment

Qilu Hospital of Shandong University, Jinan, Shandong, China

Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells

No Results Available

Use of Stem Cells for COVID-19 Treatment

Clinical outcome|CT Scan|RT-PCR results

Stem Cells Arabia

18 Years and older   (Adult, Older Adult)

Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Stem Cells Arabia, Amman, Jordan

Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia

No Results Available

2019 Novel Coronavirus Pneumonia|COVID-19

Pneumonia severity index|Oxygenation index (PaO2/FiO2)|Side effects in the UC-MSCs treatment group|28-days survival|Sequential organ failure assessment|C-reactive protein|Procalcitonin|Lymphocyte count|CD3+, CD4+ and CD8+ T celll count|CD4+/CD8+ratio

Wuhan Union Hospital, China|Wuhan Hamilton Bio-technology Co., Ltd, China.

18 Years to 65 Years   (Adult, Older Adult)

Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Phase 2|Phase 3

No Results Available

Coronavirus Infections

Mortality rate|Clinical status evaluated in agreement with guidelines|The differences in oxygen intake methods|Time of hospitalization (days)|Time of hospitalization in intensive care units|Pulmonary function

University of Catanzaro|Azienda Ospedaliera Pugliese Ciaccio|Azienda Ospedaliera Policlinico "Mater Domini"

18 Years to 75 Years   (Adult, Older Adult)

Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care

Luca Gallelli, Catanzaro, Italy

No Results Available

Biomarkers expression|Liver Biomarkers expression|biomarkers expression (microRNAs, oxidative stress, IL-2, IL-6, TNF-alfa, leukocytes, subtypes lymphocytes) after treatment

University of Catanzaro|Azienda Ospedaliera Pugliese Ciaccio|Azienda Ospedaliera Policlinico "Mater Domini"

14 Years to 75 Years   (Child, Adult, Older Adult)

Observational Model: Case-Control|Time Perspective: Prospective

Luca Gallelli, Catanzaro, Italy

No Results Available

Coronavirus Disease (COVID-19)

The change of pneumonia severity on X-ray images

First Affiliated Hospital of Fujian Medical University

18 Years to 80 Years   (Adult, Older Adult)

Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Wan-Jin Chen, Fuzhou, China